期刊
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
卷 20, 期 6, 页码 547-552出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.med.0000436191.87727.ec
关键词
bone disease; cystic fibrosis transmembrane conductance regulator; cystic fibrosis; fracture
资金
- American Society for Bone and Mineral Research
- NIH [K08DK094784, R21AR056826]
Purpose of reviewThis review will describe the clinical significance, pathogenesis and treatment of cystic fibrosis related bone disease (CFBD).Recent findingsCFBD continues to increase as the life expectancy of individuals with cystic fibrosis increases. According to clinical guidelines, individuals with cystic fibrosis should be initially screened at the age of 18 years via dual-energy x-ray absorptiometry, if not done so previously. The underlying pathogenesis of CFBD appears to be multifactorial, but increasing data imply a direct impact by the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR deficiency and/or dysfunction impair osteoblast activity and differentiation, and indirectly promote osteoclast formation. Unfortunately, once diagnosed with CFBD, few cystic fibrosis tested medical therapies exist.SummaryCFBD is an increasingly recognized complication that has a significant impact on the overall health of the individual. Recommendations to identify patients with cystic fibrosis who are at risk for fracture using dual-energy x-ray absorptiometry have been established. Therapeutic agents directly studied in patients with cystic fibrosis are limited to bisphosphonates, although other potential treatment agents exist. Finally, an improved understanding of the pathologic mechanisms will aid in the study and development of therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据